SELLAS Life Sciences Group, Inc. (SLS) News

SELLAS Life Sciences Group, Inc. (SLS): $3.30

0.18 (+5.77%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SLS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 392

in industry

Filter SLS News Items

SLS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SLS News Highlights

  • SLS's 30 day story count now stands at 6.
  • Over the past 5 days, the trend for SLS's stories per day has been choppy and unclear. It has oscillated between 3 and 3.
  • The most mentioned tickers in articles about SLS are GPS, MRK and PATH.

Latest SLS News From Around the Web

Below are the latest news stories about SELLAS Life Sciences Group Inc that investors may wish to consider to help them evaluate SLS as an investment opportunity.

Sellas, Merck complete enrollment in GPS-Keytruda combo phase 1/2 trial in ovarian cancer

Sellas Life Sciences (SLS +0.9%) completed enrollment in a phase 1/2 trial of its lead asset galinpepimut-S (GPS) in combination with Merck’s (MRK +0.1%) Keytruda (pembrolizumab) in second or third line Wilms Tumor-1 (WT1)(+) relapsed or refractory metastatic ovarian cancer. The total expected enrolled and evaluable number of patients is 17....

Seeking Alpha | February 1, 2022

SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer

Joint Development Committee of SELLAS and Merck Agreed on Study Completion and Overall Operational Path Towards Data Analysis Interim Data for 15 Evaluable Patients Expected in Mid-2022 with Final Data for up to 17 Patients in Q4 2022 NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, announced t

Yahoo | February 1, 2022

Sellas Life Sciences'' IND application for galinpepimut-S accepted in China

SELLAS Life Sciences Group (SLS) announces that an IND application to initiate the first clinical trial in China for 3D189, also known as galinpepimut-S ((GPS)), has been accepted

Seeking Alpha | January 27, 2022

SELLAS Life Sciences Announces IND Acceptance for First Clinical Trial of GPS in China

Chinese Partner, 3D Medicines, Expects to Initiate Trial in Second Half of 2022 in Patients with Hematological Malignancies Who Achieved Objective Response After Receiving Standard TreatmentNEW YORK, Jan. 26, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that an IND application to initiate the

Yahoo | January 27, 2022

SELLAS Life Sciences Promotes John Burns to Senior Vice President, Finance and Chief Accounting Officer

NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that John T. Burns has been promoted within the Company to Senior Vice President, Finance, and Chief Accounting Officer. “John is an invaluable member of our small, yet nimble SELLAS team. He consistently demonstrates his expertise

Yahoo | January 5, 2022

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | December 21, 2021

SELLAS Life Sciences Group (TSE:SLS) Hits New 12-Month High Following Analyst Upgrade

SELLAS Life Sciences Group Inc (TSE:SLS)s stock price reached a new 52-week high during trading on Thursday after TD Securities raised their price target on the stock from C$21.00 to C$22.00. TD Securities currently has a speculative buy rating on the stock. SELLAS Life Sciences Group traded as high as C$15.21 and last traded at []

Transcript Daily | December 16, 2021

Common Cancer-associated Antigens (CAAs) Vaccine Market to Witness Huge Growth by Key Players: Seattle Genetics, Merck KGaA, Merck KGaA, GlaxoSmithKline, SELLAS Life Sciences

The Common Cancer-associated Antigens (CAAs) Vaccine research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and

OpenPR | December 15, 2021

SELLAS Life Sciences Group (TSE:SLS) Stock Price Up 0.5%

SELLAS Life Sciences Group Inc (TSE:SLS)s share price was up 0.5% during mid-day trading on Wednesday . The stock traded as high as C$14.24 and last traded at C$14.19. Approximately 361,992 shares changed hands during trading, an increase of 105% from the average daily volume of 176,645 shares. The stock had previously closed at C$14.12. []

Transcript Daily | December 15, 2021

Cantor Fitzgerald Trims SELLAS Life Sciences Group (NASDAQ:SLS) Target Price to $16.00

SELLAS Life Sciences Group (NASDAQ:SLS) had its price target reduced by Cantor Fitzgerald from $18.00 to $16.00 in a report issued on Friday, The Fly reports. They currently have an overweight rating on the stock. Several other research analysts also recently commented on the stock. Zacks Investment Research downgraded shares of SELLAS Life Sciences Group []

Dakota Financial News | December 6, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4571 seconds.